  Searching for potential active compounds in large databases is a necessary
step to reduce time and costs in modern drug discovery pipelines. Such virtual
screening methods seek to provide predictions that allow the search space to be
narrowed down. Although cheminformatics has made great progress in exploiting
the potential of available big data, caution is needed to avoid introducing
bias and provide useful predictions with new compounds. In this work, we
propose the decision-support tool ALMERIA (Advanced Ligand Multiconformational
Exploration with Robust Interpretable Artificial Intelligence) for estimating
compound similarities and activity prediction based on pairwise molecular
contrasts while considering their conformation variability. The methodology
covers the entire pipeline from data preparation to model selection and
hyperparameter optimization. It has been implemented using scalable software
and methods to exploit large volumes of data -- in the order of several
terabytes -- , offering a very quick response even for a large batch of
queries. The implementation and experiments have been performed in a
distributed computer cluster using a benchmark, the public access DUD-E
database. In addition to cross-validation, detailed data split criteria have
been used to evaluate the models on different data partitions to assess their
true generalization ability with new compounds. Experiments show
state-of-the-art performance for molecular activity prediction (ROC AUC:
$0.99$, $0.96$, $0.87$), proving that the chosen data representation and
modeling have good properties to generalize. Molecular conformations --
prediction performance and sensitivity analysis -- have also been evaluated.
Finally, an interpretability analysis has been performed using the SHAP method.
